The newly identified miR-19b-3p/TNFAIP3/NF-κB axis sheds light on a novel molecular mechanism for NPC cell radioresistance, indicating that miR-19b-3p is a valuable biomarker and a promising therapeutic target for the management of NPC. The gene discussed is TNFAIP3; the disease is nasopharyngeal carcinoma.